Investment Rating - The investment rating for the company is "Outperform" [6][20][21] Core Insights - The company achieved robust revenue growth of 19.72% year-on-year in 2023, reaching RMB 396 million, despite a significant decline in net profit attributable to shareholders, which fell by 38.78% to RMB 31 million [13][31] - The decline in profit was attributed to increased R&D expenses, which rose by 33.10%, and a 36.25% increase in sales expenses aimed at expanding key industry clients [13][31] - The company is expanding its presence in Hong Kong by establishing a digital wind tunnel assessment center, investing HKD 100 million, which will focus on smart cities and digital infrastructure [14][31] - The company's "digital wind tunnel" product system has been successfully deployed across various sectors, generating RMB 101 million in revenue in 2023 [37] - The cyber range products have shown strong performance, with revenue of RMB 232 million, reflecting a year-on-year growth of 23.12% [37] Financial Performance Summary - In 2023, the company reported total revenue of RMB 396 million, with a projected revenue increase to RMB 506 million in 2024, RMB 635 million in 2025, and RMB 803 million in 2026 [7][11][38] - The net profit is expected to recover to RMB 60 million in 2024, RMB 100 million in 2025, and RMB 129 million in 2026, with corresponding EPS of RMB 0.87, RMB 1.45, and RMB 1.86 [11][38] - The gross margin is projected to remain stable around 55% over the next few years [11][38] Market Position and Strategy - The company is positioned as a leader in the cyber range market, holding significant market share and industry influence, and has received the first national certification for its cyber range products in China [37] - The strategic partnerships with entities like China Unicom and the Ministry of Industry and Information Technology are expected to enhance the company's growth prospects [38] - The company aims to replicate its mainland security assessment experience in Hong Kong, promoting its products internationally [14][31]

Equity – Asia Research | --- | --- | |---------------------------------------|-------| | | | | 孙小涵 Xiaohan Sun xh.sun@htisec.com | | | 2024 年 6 月 4 日 | | 本研究报告由海通国际分销，海通国际是由海通国际研究有限公司，海通证券印度私人有限公司，海通国际株式会社和海通国际证券集团其他各成员单位的证券 研究团队所组成的全球品牌，海通国际证券集团各成员分别在其许可的司法管辖区内从事证券活动。关于海通国际的分析师证明，重要披露声明和免责声明，请 参阅附录。(Pleaseseeappendix for Englishtranslation ofthedisclaimer) 卫材热熔胶行业龙头，业绩不断增长 行业竞争格局高度集中，公司进口替代空间广阔 发挥配方研发优势，不断推出新产品 风险提示 2 公司是吸收性卫生用品专用热熔胶（卫材热熔胶）的专业供应商，多年来专注于卫材热熔胶的 研发、生产和销售，产品主要包括结构胶、橡筋胶、背胶和特种胶等，下游主要用于卫生巾、 纸尿裤等吸 ...

Investment Rating - The report assigns an "Outperform" rating to the company, with a target price of 116.39 CNY for 2024, based on a price-to-sales (P/S) ratio of 9 times [41]. Core Insights - The company is positioned as a leading player in the AIGC (Artificial Intelligence Generated Content) sector, focusing on digital creative empowerment and aiming to become a globally influential software company [12][41]. - In 2023, the company achieved a revenue of 1.481 billion CNY, representing a year-on-year growth of 25.49%, and a net profit of 86.21 million CNY, which is a significant increase of 113.20% year-on-year [2][41]. - The company has launched several innovative products and upgraded existing ones to enhance AI capabilities, including the "Tianmu" multimedia model, which aims to support creators in various audio-visual fields [4][14]. Summary by Sections Financial Performance - In 2023, the company reported a total revenue of 1.481 billion CNY, with a net profit of 86 million CNY, reflecting a year-on-year growth of 25.5% and 113.2% respectively [13][41]. - The forecast for 2024 anticipates revenues of 1.788 billion CNY and a net profit of 111 million CNY, with continued growth expected in subsequent years [8][41]. Business Segments - Video Creative Segment: Expected to maintain high growth rates with projected year-on-year increases of 25% in 2024, 22% in 2025, and 20% in 2026 [41]. - Practical Tools Segment: Anticipated stable growth with a consistent year-on-year increase of 8% from 2024 to 2026 [41]. - Document Creative Segment: Expected growth rates of 15% in 2024, 12% in 2025, and 10% in 2026, driven by the integration of new technologies [41]. - Drawing Creative Segment: Projected growth rates of 20% in 2024, 15% in 2025, and 12% in 2026, benefiting from advancements in text models [41]. Product Development and Innovation - The company has heavily invested in AI technology, with R&D expenses reaching 403 million CNY in 2023, a 15.73% increase from the previous year [14]. - New product launches include AI-driven tools for video marketing, image generation, and virtual companionship, enhancing the company's product offerings [14][41]. - The "Tianmu" model has been officially launched, marking a significant step in AI video creation capabilities [4][41]. Market Position and Strategy - The company maintains a strong focus on building a collaborative ecosystem, partnering with major tech firms like Microsoft and Huawei to enhance its AI capabilities [5][41]. - The B2B segment has shown robust growth, with a 36% increase in 2023, indicating strong demand for the company's services in the enterprise market [5][41]. Future Outlook - The company is expected to continue its growth trajectory, leveraging its advancements in AI technology and expanding its product capabilities to meet the evolving needs of creators [41].

Investment Rating - The report gives an "Outperform" rating for the company, with a target price of 7.27 RMB based on a 25X PE for 2024 [42]. Core Viewpoints - The company has successfully reversed its previous difficulties and is now entering a stable growth phase, achieving a revenue of 6.733 billion RMB in 2023, a year-on-year increase of 12.20% [63]. - The company focuses on the traditional Chinese medicine (TCM) health sector, emphasizing resource integration and continuous optimization of its business structure [63]. - The company aims to enhance its brand strategy and product matrix, with plans to increase the sales scale of its key products [41]. Summary by Sections 1. Business Strategy and Performance - The company has gradually divested non-core businesses and is concentrating on the TCM health sector, which has led to improved operational efficiency and profitability [60][63]. - The company reported a net profit of 554 million RMB in 2023, reflecting a 14.60% year-on-year growth, indicating a recovery to historical performance levels [63][24]. 2. Product and Brand Development - The company has established a "one body, two wings" product strategy, focusing on a full range of TCM products while also developing specialty chemical drugs and health consumer products [14][41]. - In 2023, the company achieved sales of over 1 billion RMB for 17 product series, contributing to 68.6% of total revenue [41][14]. 3. Research and Development - The company has increased its R&D investment, with a R&D expense ratio of 4.43% in 2023, up nearly 1 percentage point from 2021 [5][7]. - The company is actively pursuing innovative drug development, with 200 ongoing projects, including 57 new projects initiated in 2023 [7][8]. 4. Financial Performance - The company’s revenue from TCM health products reached 4.544 billion RMB in 2023, a 16.13% increase from the previous year, accounting for 67.49% of total revenue [26][28]. - The company’s gross profit margin has stabilized, with a non-GAAP net profit margin of 8.32% in 2023, reflecting improved profitability [30][32]. 5. Market Position and Competitive Advantage - The company has strengthened its market position in the non-prescription drug sector, ranking among the top 10 non-prescription drug manufacturers in China [35][41]. - The company is leveraging digital marketing and e-commerce partnerships to expand its market reach and enhance brand visibility [33][41].

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 9.81 RMB based on a 15x 2024 PER [41][50]. Core Insights - Wool prices have stabilized in Q1 2024, showing a 3.2% increase from Q4 2023, although down 17% year-on-year, indicating potential recovery in raw material prices which could positively impact the company's earnings [1]. - The company is diversifying its product offerings and implementing a "broadband strategy" to enhance market competitiveness, focusing on high-value textile applications and expanding its global presence [2][3]. - The company has established international sales and production bases, including plans for a new production facility in Vietnam, aimed at improving supply chain efficiency and capturing overseas market share [3]. Summary by Sections Wool Price Trends - Wool prices peaked in early February 2023 and fell 27% by early November, but have since shown signs of recovery, with an average price of 768.5 US cents/kg in Q1 2024 [1]. Business Strategy - The company is expanding its yarn product range and exploring high-value applications in various sectors, including home textiles and industrial uses, while also developing functional yarns for outdoor sports [2]. - The integration of resources from New Australian Cashmere and British Duncan aims to enhance the company's global influence and market share in cashmere yarn [2]. Global Expansion - The company has a strong international presence with offices in multiple countries and is enhancing its competitiveness through global operations [3]. - The establishment of a production base in Vietnam is part of the strategy to improve supply chain delivery and increase market share [3]. Financial Projections - The company expects net earnings to reach 478 million RMB, 574 million RMB, and 658 million RMB for 2024, 2025, and 2026 respectively, with projected revenue growth of 14.4%, 13.5%, and 15.3% during the same period [41][50].

Outperform: The stock's total return over the next 12-18 months is expected to exceed the return of its relevant broad market benchmark, as indicated below. Neutral: The stock's total return over the next 12-18 months is expected to be in line with the return of its relevant broad market benchmark, as indicated below. For purposes only of FINRA/NYSE ratings distribution rules, our Neutral rating falls into a hold rating category. Underperform: The stock's total return over the next 12-18 months is expected ...

Investment Rating - The report assigns an "Outperform" rating to the company, with a target price of RMB 30.66 for the next six months, based on a projected PE of 45 for 2024 [19]. Core Insights - The company's AIoT business and international expansion are driving steady growth, with expectations for significant advancements in AIGC product deployment in 2024 [19][24]. - The company achieved a revenue of RMB 2.228 billion in 2023, marking a 12% year-on-year increase, and a net profit of RMB 150 million, also up 12% [15][19]. - The AIoT revenue reached RMB 517 million, a 42.02% increase, with contract values growing by 92% [16][24]. Financial Performance Summary - Revenue and profit forecasts for 2024-2026 are projected at RMB 2.667 billion, RMB 3.135 billion, and RMB 3.744 billion, with net profits of RMB 184 million, RMB 208 million, and RMB 267 million respectively [19][22]. - The company’s gross margin is expected to improve from 61.9% in 2023 to 66.2% by 2026, while net profit margin is projected to be around 7.1% in 2026 [22]. - Earnings per share (EPS) are forecasted to grow from RMB 0.56 in 2023 to RMB 0.99 in 2026 [22]. Business Expansion and Innovations - The company has doubled its Southeast Asian customer orders, with significant growth in both continental and non-continental revenues [28][35]. - A new generation PLM system was launched, contributing to a 34% increase in revenue from R&D and design services [29]. - The Athena platform has developed nearly 20 new digital applications, enhancing data interaction and knowledge access for over 120 customers [31][36].

Investment Rating - The report assigns an "OUTPERFORM" rating to the company with a target price of RMB 52.50 [1]. Core Insights - The company reported a revenue of RMB 22.59 billion for 2023, representing a year-on-year growth of 13.59%, and a net profit attributable to shareholders of RMB 1.41 billion, up 11.90% year-on-year [2][7]. - The company continues to expand its store count, surpassing 10,000 stores, with a total of 13,920 stores by Q1 2024. It plans to add 4,000 new stores in 2024 [2][8]. - The outpatient coordinated care policies are advancing, which is expected to benefit leading chain pharmacies like the company [2][8]. - The retail business generated revenue of RMB 20.19 billion, growing by 12.00% year-on-year, while the wholesale business saw a significant increase of 39.23% year-on-year, reaching RMB 1.89 billion [2][8]. - The company has shown improvement in its expense ratios, with a gross profit margin of 38.21% and a net profit margin of 7.00% [2][8]. Financial Summary - For 2023, the company achieved a revenue of RMB 22.59 billion, with a net profit of RMB 1.41 billion. The revenue for Q4 2023 was RMB 6.70 billion, with a net profit of RMB 0.41 billion [2][7]. - The company expects net profits for 2024-2026 to be RMB 1.77 billion, RMB 2.17 billion, and RMB 2.67 billion, with growth rates of 25.5%, 22.4%, and 22.8% respectively [2][8]. - The projected revenue for 2024 is RMB 27.62 billion, with a year-on-year growth of 22.3% [3][6].

Investment Rating - The investment rating for the company is "OUTPERFORM" with a target price of RMB 38.69 [2][12]. Core Insights - The company reported a revenue of RMB 8.94 billion in 2023, representing a year-on-year increase of 7.23%, with a gross profit margin (GPM) of 31.17%, up 0.89 percentage points. The net profit attributable to shareholders was RMB 1.51 billion, up 11.09% year-on-year [3][10]. - In Q4 2023, revenue reached RMB 2.86 billion, up 11.02% year-on-year, with a GPM of 32.44%, and net profit attributable to shareholders was RMB 0.56 billion, up 27.16% year-on-year [10][11]. - For Q1 2024, revenue was RMB 2.58 billion, up 38.34% year-on-year, with net profit attributable to shareholders of RMB 0.52 billion, up 157.03% year-on-year [10][11]. Financial Performance - The company's revenue for 2023 was RMB 89.38 billion, with a gross profit margin of 31.17% and a net profit of RMB 15.13 billion [3][5]. - The forecast for 2024-2026 projects revenues of RMB 111.92 billion, RMB 137.79 billion, and RMB 165.70 billion, with net profits of RMB 21.15 billion, RMB 27.41 billion, and RMB 34.15 billion respectively [4][12]. - The company’s gross profit margin is expected to improve to 32.2% in 2024 and further to 33.5% by 2026 [5][8]. Business Segments - The enterprise communication segment generated revenue of RMB 58.7 billion in 2023, up 6.82% year-on-year, with a GPM of 34.51% [3][11]. - The automotive segment saw revenue of RMB 21.58 billion, up 13.74% year-on-year, with a GPM of 25.65% [3][11]. - AI-related revenue reached RMB 12.4 billion, a significant increase of 186% year-on-year, driving growth in the enterprise communication segment [3][11]. International Operations - Overseas revenue accounted for RMB 72.18 billion in 2023, up 14.67% year-on-year, representing 80.75% of total revenue [4][11]. - The construction of the Thai factory is progressing, with an investment of RMB 1.4 billion and 27% completion by the end of 2023 [4][11]. Expense Management - The company reported sales, management, and financial expense ratios of 3.13%, 2.19%, and -0.76% respectively in 2023 [4][11]. - R&D expenses increased by 15% year-on-year to RMB 0.54 billion, with an expense ratio of 6.03% [4][11].

Investment Rating - The report assigns an "Outperform" rating to the company, with a target price of RMB 68.15 per share, corresponding to a market capitalization of RMB 16.86 billion [26][33]. Core Insights - The company is experiencing a significant increase in regular vaccine sales, with a revenue of RMB 360 million in 2023, despite a 65% year-over-year decline due to reduced COVID-19 vaccine revenue [22][25]. - The company has a rich pipeline of vaccines in various stages of development, including PCV13i, DTcP, Tdcp, and others, indicating strong future growth potential [7][23]. - The financial outlook shows projected revenues of RMB 840 million, RMB 1.16 billion, and RMB 1.98 billion for 2024-2026, with expected year-over-year growth rates of 136%, 38%, and 70% respectively [20][33]. Financial Performance Summary - In Q1 2024, the company reported revenue of RMB 110 million, a 14% increase year-over-year, but a net loss of RMB 170 million attributable to shareholders [31]. - The company’s operating cash flow showed a net outflow of RMB 110 million in Q1 2024, with a sales expense ratio of 41%, a G&A expense ratio of 32%, and a R&D expense ratio of 85% [31][14]. - The projected net losses for 2024, 2025, and 2026 are RMB 400 million, RMB 120 million, and a net profit of RMB 130 million, respectively [20][33]. Business Segmentation and Revenue Forecast - The company’s revenue from its two meningococcal conjugate vaccines reached approximately RMB 560 million in 2023, reflecting a 266% year-over-year increase [22][25]. - The revenue forecast for the company’s various vaccine segments indicates a recovery and growth trajectory, with significant contributions expected from the meningococcal vaccines and other pipeline products [8][20]. Research and Development Pipeline - The company has a diverse R&D pipeline, with multiple vaccines in clinical trials, including a recombinant herpes zoster vaccine and a recombinant polio vaccine, showcasing its commitment to innovation in the vaccine sector [7][23][9]. - The Phase I clinical results for the global innovative recombinant pneumococcal protein vaccine (PBPV) have shown promising safety and efficacy, indicating potential for future market success [32][31].